DexCom, Inc. (BVMF:D1EX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 174.16B +9.5% |
| Revenue (ttm) | 25.74B +15.5% |
| Net Income | 5.18B +74.9% |
| EPS | 13.14 +77.4% |
| Shares Out | n/a |
| PE Ratio | 33.63 |
| Forward PE | 31.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22 |
| Open | 8.77 |
| Previous Close | 8.77 |
| Day's Range | 8.77 - 9.25 |
| 52-Week Range | 5.75 - 9.57 |
| Beta | 1.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial numbers in USD Financial StatementsNews
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
Dexcom Appoints Glenn Boehnlein to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2...
DexCom Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong CONNECT trial results and expanded coverage are expected to drive growth, with CMS decisions anticipated by mid-2027. Product innovation, including the 15-Day sensor and AI-driven features, supports margin expansion and global adoption. Financial guidance remains at 10%+ growth, with margin improvement and new launches on track.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Technical indicators have turned bullish for the three stocks.
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Septembe...
The Big 3: PH, DXCM, UNP
Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportuni...
Dexcom raises annual revenue forecast on strong demand for glucose monitors
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar lev...
DexCom Earnings Call Transcript: Q2 2026
Q2 2026 delivered 13% revenue growth, record new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance was raised for revenue and margins, with continued growth expected as G7 15-day adoption accelerates.
DexCom Slides: Q2 2026
DexCom has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
DexCom Earnings release: Q2 2026
DexCom released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
DexCom Quarterly report: Q2 2026
DexCom has published its Q2 2026 quarterly earnings report on July 30, 2026.
Dexcom Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participa...
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Gluc...
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will...
Dexcom Further Advances Vision of Glucose Biosensing for All
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucos...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
FDA clears first over-the-counter glucose monitor for children
The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor System to children with diabetes, making it the first over-the-counter continuous glu...
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were sto...
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, acc...
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically si...
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for peop...
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, heal...